Adaptative resistance to anticancer-therapies

Group leader
Pr Caroline Robert

Contact
Widad FOURAR-LAIDI
Tél. : +33 (0)1.42.11.56.30
E-mail

 

Frise Banner: 
Adaptative resistance to anticancer-therapies

Major publications

  • Shen S et al. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nat Commun. 2019; 10(1):5713.
  • Cerezo M, Guemiri R et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma Nat Med. 2018 (12):1877-1886
  • Malka-Mahieu H et al. Molecular Pathways:  The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.  Clin Cancer Res. 2017; 23(1):21-25.
  • Boussemart L et al. Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. Cancer Res. 2016; 76(6):1476-84.
  • Boussemart L et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014; 513(7516):105-9
  • Garrido MF et al. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clin Cancer Res. 2019; 25(2):710-723.
  • Al Nakouzi N et al. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Mol Med. 2016; 8(7):761-78.
  • Faugeroux V et al. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. Eur Urol Oncol. 2019 Jan 4.
  • Massard C et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017;7(6):586-595.
Catégorie de la page: